Clinical Trials Logo

Clinical Trial Summary

The clinical trial is designed as a national, prospective, single-center, double-blind, parallel group, randomized, controlled, interventional trial to investigate whether a therapy with HCT compared with placebo can affect dermal photosensitivity and DNA stability.


Clinical Trial Description

Previously published retrospective analyses leading to the official warning about the use of hydrochlorothiazide (HCT). The underlying pilot study examins, if the intake of HCT leads to increased dermal photosensitivity and in combination with UV-exposition to a DNA-damage of the skin. Up until today, there is no prospective, randomized, placebo-controlled trial investigating the impact of HCT on dermal photosensitivity in greater detail. The pilot trial is designed as feasibility study to clarify the impact of HCT on dermal photosensitivity. This may facilitate evidence-based recommendations as to whether or not HCT increases the risk for skin cancer. Of note, HCT is one of most frequently prescribed drugs in Germany. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04654312
Study type Interventional
Source Universität des Saarlandes
Contact
Status Completed
Phase Phase 1
Start date January 18, 2021
Completion date July 22, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT04520217 - Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects Phase 1
Completed NCT04811079 - The Role of Spectral Filtering in a Spectrally Adjustable Ocular Photosensitivity Analyzer N/A
Completed NCT01942564 - The Head Injury-associated Photosensitivity and Pupillary Function (HIPP) Study N/A